Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News

Welcome to the Cambridge Angels

Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News
Exonate diabetic macular oedema asset passes phase Ib/2a challenge
29 November 2023
Guest User
Exonate diabetic macular oedema asset passes phase Ib/2a challenge
Guest User
29 November 2023

Exonate diabetic macular oedema asset passes phase Ib/2a challenge

Guest User
29 November 2023

Source:https://www.cambridgeindependent.co.uk/business/exonate-boost-for-first-topical-diabetic-macular-oedema-trea-9342197/

Newer PostForefront RF’s patented tunable duplexer technology officially trademarked
Older Post'Revolutionary' liquid barrier dressing for cattle
LI-In-Bug_small.png
Back to Top
Privacy
info@cambridgeangels.net